Fulgent Genetics Stock
Fulgent Genetics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Country
- United States
- CEO
- Ming Hsieh
- Employees
- 1,315
- Market cap
- $545 M
- IPO
- 29/09/2016
Fulgent Genetics, Inc., together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers a wide range of applications, including extensive oncology panels…
Fulgent Genetics stock: price history
1D
-7.2%
1W
-8.9%
1M
-8.4%
6M
+21.8%
YTD
-24.6%
1Y
-13.1%
2Y
-1.4%
5Y
-74.6%
10Y
+142.5%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~43% stronger price swings than usual
Ask the agents about Fulgent Genetics
Analyst assessment of Fulgent Genetics
PRICE TARGET LOW
US$19.00
CONSENSUS
US$19.00
MEDIAN
US$19.00
PRICE TARGET HIGH
US$19.00
0
STRONG BUY
6
BUY
3
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 04/08/2026
Fulgent Genetics stock metrics
P/E
-7.02
P/B
0.55
EV/EBITDA
-8.12
RETURN ON EQUITY
-2.9%
NET MARGIN
-34.6%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
60.7%
FLOAT SHARES
16,691,052
AVG. DAILY VOLUME (30D)
321,201
Insider transactions (SEC)
Gao Hanlin
Hsieh Ming
Kim Paul
Xie Jian
Xie Jian
Institutional holders
Comparable stocks
Frequently asked questions about Fulgent Genetics stock
What does Fulgent Genetics do?
Fulgent Genetics, Inc. is a company in the Healthcare sector, Medical - Diagnostics & Research industry, headquartered in United States.
The CEO is Ming Hsieh, the company employs around 1,315 people.
The IPO was on 29/09/2016; the stock trades on NASDAQ under the ticker FLGT.
What do analysts say about Fulgent Genetics stock?
9 analysts rate the stock, the consensus is Buy (as of 04/08/2026).
The average price target is US$19.00, ranging from US$19.00 to US$19.00, with a median of US$19.00.
This is an external assessment, not a statement by Market Jury.
When does Fulgent Genetics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 43% stronger than usual.
Does Fulgent Genetics pay a dividend?
No, Fulgent Genetics currently does not pay a dividend.
Which stocks are comparable to Fulgent Genetics?
Comparable stocks include Thermo Fisher Scientific, Danaher, Natera, Agilent Technologies, IQVIA Holdings, Waters, Illumina and IDEXX Laboratories.
How can I get Fulgent Genetics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Fulgent Genetics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.